NEW YORK — Swedish cancer diagnostics firm Immunovia said on Thursday that it has raised approximately SEK 398 million ($43.0 million) in gross proceeds through the sale of stock to certain institutional investors.
Through the transaction, Immunovia issued 2,948,228 million shares of its stock at a price of SEK 135 apiece to both international and domestic investors. Kempen & Co and Danske Bank acted as joint global coordinators, as well as joint bookrunners along with Vator Securities.